REG - Yourgene Health PLC - Director/PDMR Shareholding

Yourgene HealthAnnouncement

29/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221229:nRSc1289La&default-theme=true

RNS Number : 1289L  Yourgene Health PLC  29 December 2022

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Director/PDMR Shareholding

 

Manchester, UK - 29 December 2022: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, announces that it was notified on
28 December 2022 that Hayden Jeffreys, Chief Operating Officer of the Company,
purchased 3,138,538 ordinary shares of 0.1p each in the Company ("Ordinary
Shares") on 28 December 2022 at a price of 0.366p per share. Following the
purchase, Hayden Jeffreys is interested in 3,827,482 Ordinary Shares,
representing approximately 0.5 per cent. of the Company's issued share
capital.

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 

 Yourgene Health plc                             Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer               investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Cairn Financial Advisers LLP (NOMAD)            Tel: +44 (0)20 7213 0880
 Liam Murray / Ludovico Lazzaretti

 Singer Capital Markets (Corporate Broker)       Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
 Paul McManus / Lianne Applegarth                Mob: 07980 541 893 / Mob: 07584 391 303

 

 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops
and commercialises integrated genomic technologies and services enabling
genomic medicine in over 60 territories. The group works in partnership with
global leaders in DNA technology to advance diagnostic science and support
precision medicine.

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and an extension into the precision medicine space with DPYD genotyping.

Yourgene has a range of innovative DNA sample preparation platforms, and
launched Yourgene Genomic Services in 2020, which has enabled Yourgene to
offer a global laboratory service network equipped to provide high quality
genetic testing and bioinformatics solutions and serve as a full life-cycle
partner for clinical, research and pharmaceutical organisations to support
partners at the preclinical, clinical, and post-market stages to develop,
manufacture, obtain regulatory approval and commercialise new products and
services.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Hayden Jeffreys

 2    Reason for the notification

 a)   Position/status                                              Chief Operating Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Yourgene Health plc

 b)   LEI                                                          213800UUIT8BZE7QEH33

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of 0.1p each

      Identification code                                          ISIN: GB00BN31ZD89

 b)   Nature of the transaction                                    Purchase of ordinary shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     0.366p            3,138,538

 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      28 December 2022

 f)   Place of the transaction                                     UK

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHKVLFLLLLLFBX